Nexstim receives a new NBS system order from a leading California based academic hospital

News
- 07/05/2021

Helsinki, Finland : 7 May 2021 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) announces that it has received an NBS system order from a distinguished academic hospital based in Northern California, US.

Nexstim NBS systems use the unique SmartFocus® TMS technology that enables accurate stimulation of the targeted area in the brain. The Nexstim NBS system is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain.

Mikko Karvinen, CEO of Nexstim, says: “We are happy to announce the sale of this new NBS system to a renowned academic hospital. The NBS business has been a stable source of revenue for us during the COVID-19 pandemic, and we are glad to see an increasing number of patients benefiting from our SmartFocus® TMS technology as the system will be used for motor and speech mapping purposes.”

Further information on Nexstim’s website.